- Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents
- Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024
- Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
- Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors
- Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting
- Orchestra BioMed to Participate in Upcoming Investor Conferences
- Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients
- Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years
- Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update
- Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients
More ▼
Key statistics
On Friday, Orchestra Biomed Holdings Inc (OBIO:NMQ) closed at 5.10, 20.85% above the 52 week low of 4.22 set on Apr 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.00 |
---|---|
High | 5.42 |
Low | 4.95 |
Bid | 2.05 |
Offer | 5.40 |
Previous close | 5.55 |
Average volume | 46.45k |
---|---|
Shares outstanding | 35.78m |
Free float | 21.84m |
P/E (TTM) | -- |
Market cap | 182.46m USD |
EPS (TTM) | -1.49 USD |
Data delayed at least 15 minutes, as of May 03 2024 21:00 BST.
More ▼